erythrosine has been researched along with Drop Attack in 4 studies
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Coscas, G | 1 |
Binaghi, M | 1 |
Quentel, G | 1 |
Yannuzzi, LA | 2 |
Rohrer, KT | 1 |
Tindel, LJ | 1 |
Sobel, RS | 1 |
Costanza, MA | 1 |
Shields, W | 1 |
Zang, E | 1 |
Justice, J | 1 |
Baldwin, HA | 1 |
Chazan, BI | 1 |
Balodimos, MC | 1 |
Koncz, L | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Macular Perfusion Changes in Proliferative Diabetic Retinopathy Following Anti-VEGF Therapy Versus Targeted and Pan-retinal Photocoagulation Using Optical Coherence Tomography Angiography[NCT04674254] | Phase 4 | 43 participants (Actual) | Interventional | 2021-03-30 | Active, not recruiting | ||
Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography[NCT03246152] | Phase 4 | 31 participants (Actual) | Interventional | 2017-10-23 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Correlation of BCVA change with degree of capillary non-perfusion before and after injections (NCT03246152)
Timeframe: At baseline and after 3-6 consecutive monthly injections.
Intervention | Logmar (Mean) |
---|---|
Bevacizumab Group | -0.21 |
Effect of repeated intravitreal Anti-VEGF injections on Foveal Avascular Zone (FAZ) area measured using the freehand tool of ImageJ (NCT03246152)
Timeframe: At baseline and after 3-6 consecutive monthly injections.
Intervention | mm^2 (Mean) |
---|---|
Bevacizumab Group | 0.03 |
Effect of repeated intravitreal Anti-VEGF injections on macular capillary density using the change in the skeletonized vascular density and fractal dimension measured by ImageJ (NCT03246152)
Timeframe: At baseline and after 3-6 consecutive monthly injections.
Intervention | percentage of vascularity (Mean) |
---|---|
Bevacizumab Group | -2.5 |
2 reviews available for erythrosine and Drop Attack
Article | Year |
---|---|
[Incidents and accidents in fluorescence angiography].
Topics: Brain Diseases; Cardiomyopathies; Fluorescein Angiography; Fluoresceins; Humans; Hypersensitivity; N | 1982 |
Fluorescein angiography complication survey.
Topics: Fluorescein; Fluorescein Angiography; Fluoresceins; Health Surveys; Heart Diseases; Humans; Nausea; | 1986 |
Fluorescein angiography complication survey.
Topics: Fluorescein; Fluorescein Angiography; Fluoresceins; Health Surveys; Heart Diseases; Humans; Nausea; | 1986 |
Fluorescein angiography complication survey.
Topics: Fluorescein; Fluorescein Angiography; Fluoresceins; Health Surveys; Heart Diseases; Humans; Nausea; | 1986 |
Fluorescein angiography complication survey.
Topics: Fluorescein; Fluorescein Angiography; Fluoresceins; Health Surveys; Heart Diseases; Humans; Nausea; | 1986 |
1 trial available for erythrosine and Drop Attack
Article | Year |
---|---|
Effective differences in the formulation of intravenous fluorescein and related side effects.
Topics: Bicarbonates; Chromatography, Thin Layer; Clinical Trials as Topic; Drug Hypersensitivity; Fluoresce | 1974 |
1 other study available for erythrosine and Drop Attack
Article | Year |
---|---|
Untoward effects of fluorescein retinal angiography in diabetic patients.
Topics: Adult; Angioedema; Blood Gas Analysis; Blood Glucose; Blood Pressure; Chlordiazepoxide; Conjunctiva; | 1971 |